NeuroGenomeX, Inc.

About NeuroGenomeX, Inc. (NGX)

NeuroGenomeX, Inc. (NGX) is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).

NeuroGenomeX, in collaboration with the NIH BrIDGs program (Bridging Interventional Development Gaps) and University of Virginia, is advancing 2DG through pre-clinical development to support a Phase 1b clinical trial in patients with intractable epilepsy. These studies are designed to establish the safety and efficacy of 2DG in epilepsy patients. NeuroGenomeX holds an exclusive world-wide license from the Wisconsin Alumni Research Foundation (WARF) for the use of 2DG to treat epilepsy and diseases of the nervous system.